Hummingbird Bioscience Announces Poster Presentation on HMBD-802, Novel Dual-Payload Antibody-Drug Conjugate, at EORTC-NCI-AACR 2024
23 oct. 2024 08h00 HE
|
Hummingbird Bioscience
Hummingbird Bioscience today announced a poster presentation on HMBD-802, a dual-payload ADC, at the 36th EORTC-NCI-AACR symposium.
BioNTech präsentiert auf dem ESMO-Kongress 2024 klinische Daten-Updates aus dem mRNA und immunmodulatorischen Onkologie-Portfolio
05 sept. 2024 07h15 HE
|
BioNTech SE
MAINZ, Deutschland, 05. September 2024 – BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) wird auf dem diesjährigen Kongress der European Society for Molecular Oncology („ESMO“), der vom...
BioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio at ESMO Congress 2024
05 sept. 2024 07h15 HE
|
BioNTech SE
MAINZ, Germany, September 05, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected assets from its multi-platform oncology pipeline at the...
Hummingbird Bioscience Announces Key Leadership Appointments
29 juil. 2024 08h00 HE
|
Hummingbird Bioscience
Hummingbird Bioscience Announces Key Leadership Appointments
• Kon Yew Kwek appointed Chief Medical Officer
• Lisa Ooi appointed Chief Operating Officer
BioNTech und DualityBio erhalten Fast-Track-Status der FDA für Antikörper-Wirkstoff-Konjugat-Kandidat BNT324/DB-1311 bei Prostatakrebs
24 juin 2024 06h45 HE
|
BioNTech SE
Der Status basiert auf präklinischen Daten und Daten aus einer laufenden Phase-1/2-Studie für BNT324/DB-1311; vorläufige klinische Phase-1/2-Daten zeigten eine Anti-Tumor-Aktivität und ein...
BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324/DB-1311 in Prostate Cancer
24 juin 2024 06h45 HE
|
BioNTech SE
Designation is based on pre-clinical data and data from an ongoing Phase 1/2 trial for BNT324/DB-1311, with antitumor activity and a manageable safety profile demonstrated by preliminary Phase 1/2...
Antibody-drug Conjugates Shift the Cancer Treatment Landscape: Novotech Whitepaper Examines Latest Clinical Trial Data
21 juin 2024 17h30 HE
|
Novotech
BOSTON, June 21, 2024 (GLOBE NEWSWIRE) -- Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of...
Hummingbird Bioscience Presents New Preclinical Data Highlighting Next-Generation Antibody-Drug Conjugate Capabilities at PEGS Boston 2024
13 mai 2024 05h30 HE
|
Hummingbird Bioscience
Hummingbird Bioscience will present next-generation antibody-drug conjugate capabilities at PEGS Boston 2024 for the first time.
Antibody Therapeutics Market to Witness Remarkable Growth with a CAGR of 13% during the Forecast Period | MarketDigits
22 févr. 2024 08h30 HE
|
PIONEERING MARKETDIGITS CONSULTING AND ADVISORY PRIVATE LIMITED
Richmond, Feb. 22, 2024 (GLOBE NEWSWIRE) -- According to MarketDigits, Antibody Therapeutics Market was valued USD 232 Billion in 2023 and projected to reach USD 535.8 Billion by 2030, growing at a...
BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325/DB-1305
31 janv. 2024 06h45 HE
|
BioNTech SE
Designation is based on preliminary safety and efficacy data from an ongoing Phase 1/2 trial in patients with platinum-resistant ovarian epithelial cancer, fallopian tube, or primary...